Danaher Co. (NYSE:DHR) Shares Sold by Cullinan Associates Inc.

Cullinan Associates Inc. lowered its position in shares of Danaher Co. (NYSE:DHR) by 27.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,300 shares of the conglomerate’s stock after selling 500 shares during the period. Cullinan Associates Inc.’s holdings in Danaher were worth $353,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at $25,000. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth about $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher during the first quarter worth about $30,000. MFA Wealth Advisors LLC acquired a new position in Danaher during the second quarter worth about $51,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher in the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. UBS Group decreased their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday. Raymond James lowered their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday. Bank of America raised their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Stock Down 1.0 %

DHR stock opened at $245.41 on Friday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company’s 50 day simple moving average is $270.00 and its 200-day simple moving average is $260.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market capitalization of $181.77 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,059 shares of company stock valued at $8,400,897. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.